Description:

SOUTHWEST ONCOLOGY GROUP S0221 FOLLOW UP FORM Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A678C302-20D3-50A8-E034-0003BA0B1A09

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A678C302-20D3-50A8-E034-0003BA0B1A09

Keywords:
Versions (3) ▾
  1. 8/26/12
  2. 3/20/14
  3. 1/9/15
Uploaded on:

January 9, 2015

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Breast Cancer NCT00070564 Follow-Up - SOUTHWEST ONCOLOGY GROUP S0221 FOLLOW UP FORM - 2050216v3.0

No Instruction available.

  1. StudyEvent: SOUTHWEST ONCOLOGY GROUP S0221 FOLLOW UP FORM
    1. No Instruction available.
Administrative documentation
Vital Status
Vital Status
Disease Follow Up Status
Has the patient had a documented clinical assessment for this cancer since submission of the previous follow-up form?
Notice Of Progression - Adjuvant
Has the patient developed a first relapse or progression that has not been previously reported
Notice Of New Primary
Has a new primary cancer, opposite breast cancer, or myelodysplastic syndrome (MDS) been diagnosed that has not been previously reported?
Non-protocol Treatment
Has the patient received any non-protocol cancer therapy (prior to progression/relapse) not previously reported?
Long Term Toxicity
Has the patient experienced any severe long term toxicity that has not been previously reported?
Comments

Similar models